Cybin submits ind application to fda for its phase 1/2a first-in-human trial of cyb003 for the treatment of major depressive disorder

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (cybin or the company), a biopharmaceutical company focused on progressing “psychedelics to therapeuticstm”, is pleased to announce the submission of an investigational new drug (“ind”) application to the u.s. food and drug administration (“fda”) for its phase 1/2a first-in-human clinical trial evaluating cyb003, a proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (“mdd”). “following the
CYBN Ratings Summary
CYBN Quant Ranking